53865-02-4

Basic information

• Product Name: 8,10-Dihydroxy-7H-benzo[c]xanthen-7-one
• Synonyms: 8,10-Dihydroxy-7H-benzo[c]xanthen-7-one;8,10-Dihydroxy-benzo[c]xanthen-7-one
• CAS NO: 53865-02-4
• Molecular Formula: C₁₇H₁₀O₄
• Molecular Weight: 278.2589
• Mol File: 53865-02-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8,10-Dihydroxy-7H-benzo[c]xanthen-7-one(CAS DataBase Reference)
• NIST Chemistry Reference: 8,10-Dihydroxy-7H-benzo[c]xanthen-7-one(53865-02-4)
• EPA Substance Registry System: 8,10-Dihydroxy-7H-benzo[c]xanthen-7-one(53865-02-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 53865-02-4(Hazardous Substances Data)

Upstream product

• 108-73-6 3,5-dihydroxyphenol 
• 86-48-6 1-hydroxy-2-naphthoic acid 
• 90-15-3 α-naphthol 
• 3147-39-5 methyl 2,4,6-trihydroxybenzoate 

Downstream Products

• 1309112-76-2 10-(benzyloxy)-8-hydroxy-7H-benzo[c]xanthen-7-one 
• 1309112-75-1 8,10-dihydroxy-9,11-bis(2-hydroxybenzyl)-7H-benzo[c]xanthen-7-one 
• 1309112-97-7 8-(3-bromobenzoyloxy)-7-oxo-7H-benzo[c]xanthen-10-yl 3-methoxybenzoate 

Relevant articles and documents

Synthesis of novel benzoxanthone analogues as non-Camptothecin topoisomerase i inhibitors

Structure modification of the side chain of the lead compound benzoxanthone provided a series of benzoxanthone analogues and 12 of them were first reported. The results showed that most of these compounds had moderate cytotoxicity against tumour cells with the 50% inhibition concentration in the micromolar range. Furthermore, benzoxanthone derivatives 5, 6c, 7a and 7e, showed potent topoisomerase I (Topo I) inhibitory effect and the results indicated that some compounds had potential for development as non-Camptothecin (CPT) topoisomerase I inhibitors.

New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers

We synthesized 12 benzoxanthone derivatives classified as three different groups based on the tetracyclic ring shapes and evaluated their pharmacological activities to find potential anticancer agents. In the cytotoxicity test, most compounds showed effective cancer cell growth inhibition against the HT29 and DU145 cell lines. Among the compounds tested, compound 19 was the most effective in the cancer cell lines tested. Compound 9 showed dual inhibitory activities against DNA relaxation by topoisomerases I and II. The% inhibition of compound 9 on topoisomerase I was comparable to that of camptothecin. Compound 9 efficiently blocked topoisomerase II function by almost threefold than etoposide at 20 μM. Compound 19 had selective topoisomerase II inhibitory activity at 100 μM. The DNA cross-linking test revealed that only compounds 8 and 19, which possess epoxy groups, cross-linked DNA duplex, while 14 did not. From the combined pharmacological results, we proposed that the target through which compound 19 inhibits cancer cell growth may be the DNA duplex itself and/or DNA-topoisomerase II complex.